CD5 Antibody [CRIS-1] | 33-084

CD5 Antibody [CRIS-1] | 33-084 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Rhesus

Homology: N/A

Immunogen: Stimulated human leukocytes were used as the immunogen for this CD5 antibody.

Research Area: Cancer, Immunology, Signal Transduction

Tested Application: Func, Flow, IF

Application: Functional Testing: order BSA/azide-free format
Flow Cytometry: 0.5-1 ug/million cells
IF: 0.5-1 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD5 antibody to be titered up or down for optimal performance.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: CRIS-1

Isotype: IgG2a, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: T-cell surface glycoprotein CD5, Lymphocyte antigen T1/Leu-1, CD5, CD5, LEU1

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: This antibody recognizes a 67kDa transmembrane protein, which is identified as CD5. It is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in Tcell areas. CD5 antibody is a pan Tcell marker that also reacts with a range of neoplastic Bcells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) , mantle cell lymphoma, and a subset (~10%) of diffuse large Bcell lymphoma. Aberrant expression is useful in making a diagnosis of mature Tcell neoplasms. CD5 antibody detection is diagnostic in CLL/SLL within a panel of other Bcell markers, especially one that includes anti-CD23. CD5 antibody is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, it can be used in distinguishing thymic carcinoma (+) from thymoma (-) . It does not react with granulocytes or monocytes.